Patients with or without HF: 1 trials - GISSI 3
| lisinopril vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Death from any cause or hospitalization for any reason | no data | | NYHA class improvement | no data | | death or severe congestive heart failure | no data | | Long term death | no data | | hospitalisation for heart failure | no data | | All cause death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Systematic early treatment (with or without sign of HF): 1 trials - GISSI 3
| lisinopril vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Death from any cause or hospitalization for any reason | no data | | NYHA class improvement | no data | | death or severe congestive heart failure | no data | | Long term death | no data | | hospitalisation for heart failure | no data | | All cause death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patient with history of atrial fibrillation: 1 trials - Van den Burg
| lisinopril vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Vascular death | no data | | atrial fibrillation recurrence | 0.45 [0.06 3.48] | p=1.00 | 0 | 18 | 1 | Van den Burg, | | more than one AF recurrence | no data | | Vascular events | no data | | hospitalisation for heart failure | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients without history of AF (primary prevention): 1 trials - GISSI-3 (AF ancillary study)
| lisinopril vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| atrial fibrillation | 0.92 [0.82 1.02] | p=1.00 | 0 | 17748 | 1 | GISSI-3 (AF ancillary study), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 1 trials - ALLHAT (lisi vs chlor, diabetic subgroup)
| lisinopril vs chlorthalidone | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.07 [0.99 1.15] | p=1.00 | 0 | 8740 | 1 | ALLHAT (lisi vs chlor, diabetic subgroup), | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 1.03 [0.94 1.13] | p=1.00 | 0 | 8740 | 1 | ALLHAT (lisi vs chlor, diabetic subgroup), | | stroke (fatal and non fatal) | 1.06 [0.89 1.26] | p=1.00 | 0 | 8740 | 1 | ALLHAT (lisi vs chlor, diabetic subgroup), | | microvascular events | no data | | Non fatal MI | no data | | All cause death | 0.99 [0.89 1.10] | p=1.00 | 0 | 8740 | 1 | ALLHAT (lisi vs chlor, diabetic subgroup), | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients with hypertension: 1 trials - ALLHAT (lisi vs chlor, diabetic subgroup)
| lisinopril vs chlorthalidone | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.07 [0.99 1.15] | p=1.00 | 0 | 8740 | 1 | ALLHAT (lisi vs chlor, diabetic subgroup), | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 1.03 [0.94 1.13] | p=1.00 | 0 | 8740 | 1 | ALLHAT (lisi vs chlor, diabetic subgroup), | | stroke (fatal and non fatal) | 1.06 [0.89 1.26] | p=1.00 | 0 | 8740 | 1 | ALLHAT (lisi vs chlor, diabetic subgroup), | | microvascular events | no data | | Non fatal MI | no data | | All cause death | 0.99 [0.89 1.10] | p=1.00 | 0 | 8740 | 1 | ALLHAT (lisi vs chlor, diabetic subgroup), | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients with or without hypertension: 1 trials - ALLHAT (lisi vs chlor, diabetic subgroup)
| lisinopril vs chlorthalidone | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.07 [0.99 1.15] | p=1.00 | 0 | 8740 | 1 | ALLHAT (lisi vs chlor, diabetic subgroup), | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 1.03 [0.94 1.13] | p=1.00 | 0 | 8740 | 1 | ALLHAT (lisi vs chlor, diabetic subgroup), | | stroke (fatal and non fatal) | 1.06 [0.89 1.26] | p=1.00 | 0 | 8740 | 1 | ALLHAT (lisi vs chlor, diabetic subgroup), | | microvascular events | no data | | Non fatal MI | no data | | All cause death | 0.99 [0.89 1.10] | p=1.00 | 0 | 8740 | 1 | ALLHAT (lisi vs chlor, diabetic subgroup), | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of heart failure: 6 trials - Zwehl - Giles - Rucinska-c (lisinopril) - Gilbert - International Study Group (Lewis) - ATLAS
| lisinopril vs control | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Death from any cause or hospitalization for any reason | 0.54 [0.21 1.34] | p=1.00 | 0 | 526 | 3 | Zwehl,Giles,Rucinska-c (lisinopril), | | NYHA class improvement | no data | | death or severe congestive heart failure | no data | | Long term death | no data | | hospitalisation for heart failure | no data | | All cause death | 0.64 [0.25 1.66] | p=1.00 | 0 | 526 | 3 | Zwehl,Giles,Rucinska-c (lisinopril), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| lisinopril vs lisinopril | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Death from any cause or hospitalization for any reason | no data | | NYHA class improvement | no data | | death or severe congestive heart failure | no data | | Long term death | no data | | hospitalisation for heart failure | no data | | All cause death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| lisinopril vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Death from any cause or hospitalization for any reason | 1.00 [0.02 55.80] | p=1.00 | 0 | 20 | 1 | Gilbert, | | NYHA class improvement | no data | | death or severe congestive heart failure | no data | | Long term death | no data | | hospitalisation for heart failure | no data | | All cause death | 0.70 [0.16 2.94] | p=1.00 | 0 | 150 | 2 | Gilbert,International Study Group (Lewis), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patient: 2 trials - ALLHAT (ACEI vs chlorthalidone) - ALLHAT (ACEI vs amlodipine)
| lisinopril vs amlodipine | No demonstrated result suggested stroke (fatal and non fatal) by 21% (not demonstrated) suggested Heart failure by 13% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.03 [0.97 1.10] | p=1.00 | 0 | 18102 | 1 | ALLHAT (ACEI vs amlodipine), | | Cardiovascular death | 1.03 [0.91 1.16] | p=1.00 | 0 | 18102 | 1 | ALLHAT (ACEI vs amlodipine), | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | 1.21 [1.05 1.39] | p=0.04 | 0 | 18102 | 1 | ALLHAT (ACEI vs amlodipine), | | Coronary event | 1.00 [0.90 1.10] | p=1.00 | 0 | 18102 | 1 | ALLHAT (ACEI vs amlodipine), | | Fatal MI | 0.93 [0.75 1.16] | p=1.00 | 0 | 18102 | 1 | ALLHAT (ACEI vs amlodipine), | | Heart failure | 0.87 [0.77 0.97] | p=0.04 | 0 | 18102 | 1 | ALLHAT (ACEI vs amlodipine), | | Diabetes onset | no data | | Peripheral arterial disease | no data | | End stage renal disease | 0.98 [0.76 1.25] | p=1.00 | 0 | 18102 | 1 | ALLHAT (ACEI vs amlodipine), | | All cause death | 1.05 [0.96 1.14] | p=1.00 | 0 | 18102 | 1 | ALLHAT (ACEI vs amlodipine), | | non cardiovascular death | 1.08 [0.96 1.22] | p=1.00 | 0 | 18102 | 1 | ALLHAT (ACEI vs amlodipine), | | Fatal stroke | 1.27 [0.97 1.68] | p=1.00 | 0 | 18102 | 1 | ALLHAT (ACEI vs amlodipine), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| lisinopril vs diuretics | No demonstrated result suggested cardiovascular events by 7% (not demonstrated) suggested stroke (fatal and non fatal) by 14% (not demonstrated) suggested Heart failure by 19% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.07 [1.01 1.14] | p=0.04 | 0 | 24309 | 1 | ALLHAT (ACEI vs chlorthalidone), | | Cardiovascular death | 1.03 [0.93 1.15] | p=1.00 | 0 | 24309 | 1 | ALLHAT (ACEI vs chlorthalidone), | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | 1.14 [1.01 1.29] | p=0.04 | 0 | 24309 | 1 | ALLHAT (ACEI vs chlorthalidone), | | Coronary event | 0.98 [0.90 1.08] | p=1.00 | 0 | 24309 | 1 | ALLHAT (ACEI vs chlorthalidone), | | Fatal MI | 0.89 [0.73 1.08] | p=1.00 | 0 | 24309 | 1 | ALLHAT (ACEI vs chlorthalidone), | | Heart failure | 1.19 [1.07 1.32] | p=0.04 | 0 | 24309 | 1 | ALLHAT (ACEI vs chlorthalidone), | | Diabetes onset | no data | | Peripheral arterial disease | no data | | End stage renal disease | 1.10 [0.88 1.38] | p=1.00 | 0 | 24309 | 1 | ALLHAT (ACEI vs chlorthalidone), | | All cause death | 1.00 [0.93 1.08] | p=1.00 | 0 | 24309 | 1 | ALLHAT (ACEI vs chlorthalidone), | | non cardiovascular death | 0.97 [0.87 1.07] | p=1.00 | 0 | 24309 | 1 | ALLHAT (ACEI vs chlorthalidone), | | Fatal stroke | 1.20 [0.94 1.52] | p=1.00 | 0 | 24309 | 1 | ALLHAT (ACEI vs chlorthalidone), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Diabetic patients : 1 trials - ALLHAT (lisi vs chlor, diabetic subgroup)
| lisinopril vs chlorthalidone | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.07 [0.99 1.15] | p=1.00 | 0 | 8740 | 1 | ALLHAT (lisi vs chlor, diabetic subgroup), | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 1.03 [0.94 1.13] | p=1.00 | 0 | 8740 | 1 | ALLHAT (lisi vs chlor, diabetic subgroup), | | stroke (fatal and non fatal) | 1.06 [0.89 1.26] | p=1.00 | 0 | 8740 | 1 | ALLHAT (lisi vs chlor, diabetic subgroup), | | microvascular events | no data | | Non fatal MI | no data | | All cause death | 0.99 [0.89 1.10] | p=1.00 | 0 | 8740 | 1 | ALLHAT (lisi vs chlor, diabetic subgroup), | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients with additional risk factor: 2 trials - ALLHAT (ACEI vs chlorthalidone) - ALLHAT (ACEI vs amlodipine)
| lisinopril vs amlodipine | No demonstrated result suggested stroke (fatal and non fatal) by 21% (not demonstrated) suggested Heart failure by 13% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.03 [0.97 1.10] | p=1.00 | 0 | 18102 | 1 | ALLHAT (ACEI vs amlodipine), | | Cardiovascular death | 1.03 [0.91 1.16] | p=1.00 | 0 | 18102 | 1 | ALLHAT (ACEI vs amlodipine), | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | 1.21 [1.05 1.39] | p=0.04 | 0 | 18102 | 1 | ALLHAT (ACEI vs amlodipine), | | Coronary event | 1.00 [0.90 1.10] | p=1.00 | 0 | 18102 | 1 | ALLHAT (ACEI vs amlodipine), | | Fatal MI | 0.93 [0.75 1.16] | p=1.00 | 0 | 18102 | 1 | ALLHAT (ACEI vs amlodipine), | | Heart failure | 0.87 [0.77 0.97] | p=0.04 | 0 | 18102 | 1 | ALLHAT (ACEI vs amlodipine), | | Diabetes onset | no data | | Peripheral arterial disease | no data | | End stage renal disease | 0.98 [0.76 1.25] | p=1.00 | 0 | 18102 | 1 | ALLHAT (ACEI vs amlodipine), | | All cause death | 1.05 [0.96 1.14] | p=1.00 | 0 | 18102 | 1 | ALLHAT (ACEI vs amlodipine), | | non cardiovascular death | 1.08 [0.96 1.22] | p=1.00 | 0 | 18102 | 1 | ALLHAT (ACEI vs amlodipine), | | Fatal stroke | 1.27 [0.97 1.68] | p=1.00 | 0 | 18102 | 1 | ALLHAT (ACEI vs amlodipine), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| lisinopril vs diuretics | No demonstrated result suggested cardiovascular events by 7% (not demonstrated) suggested stroke (fatal and non fatal) by 14% (not demonstrated) suggested Heart failure by 19% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.07 [1.01 1.14] | p=0.04 | 0 | 24309 | 1 | ALLHAT (ACEI vs chlorthalidone), | | Cardiovascular death | 1.03 [0.93 1.15] | p=1.00 | 0 | 24309 | 1 | ALLHAT (ACEI vs chlorthalidone), | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | 1.14 [1.01 1.29] | p=0.04 | 0 | 24309 | 1 | ALLHAT (ACEI vs chlorthalidone), | | Coronary event | 0.98 [0.90 1.08] | p=1.00 | 0 | 24309 | 1 | ALLHAT (ACEI vs chlorthalidone), | | Fatal MI | 0.89 [0.73 1.08] | p=1.00 | 0 | 24309 | 1 | ALLHAT (ACEI vs chlorthalidone), | | Heart failure | 1.19 [1.07 1.32] | p=0.04 | 0 | 24309 | 1 | ALLHAT (ACEI vs chlorthalidone), | | Diabetes onset | no data | | Peripheral arterial disease | no data | | End stage renal disease | 1.10 [0.88 1.38] | p=1.00 | 0 | 24309 | 1 | ALLHAT (ACEI vs chlorthalidone), | | All cause death | 1.00 [0.93 1.08] | p=1.00 | 0 | 24309 | 1 | ALLHAT (ACEI vs chlorthalidone), | | non cardiovascular death | 0.97 [0.87 1.07] | p=1.00 | 0 | 24309 | 1 | ALLHAT (ACEI vs chlorthalidone), | | Fatal stroke | 1.20 [0.94 1.52] | p=1.00 | 0 | 24309 | 1 | ALLHAT (ACEI vs chlorthalidone), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
